Stay updated on Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel
Sign up to get notified when there's something new on the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page.

Latest updates to the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded a glossary toggle and updated QC metadata to show 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', replacing the previous capitalization and version text.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no substantive changes to the study details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedLocations were updated with many new sites across multiple countries and regions and some sites were removed, changing where eligible participants can enroll.SummaryDifference2%

- Check68 days agoChange DetectedA new site revision tag Revision: v3.3.2 appears, replacing Revision: v3.3.1. This is a minor metadata update and does not affect study details or user-facing content.SummaryDifference0.0%

- Check75 days agoChange DetectedPublications note updated to clarify that PubMed publications are automatically filled from PubMed, and a revision tag now shows v3.3.1.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page-level funding status notice was removed. The study details, outcomes and locations remain unchanged.SummaryDifference0.1%

Stay in the know with updates to Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel
Enter your email address, and we'll notify you when there's something new on the Clinical Trial HER2+ Breast Cancer Trastuzumab-Paclitaxel page.